drugset

drugset / Trial / NCT07794670

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

NCT07794670 ↗

Phase 2 Recruiting 400 enrolled NewAmsterdam Pharma

RandomizedParallel-groupTriple-blindPrevention

Summary

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Timeline

Start: 2026-09
Primary completion: 2028-09
Completion: 2029-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Obicetrapib	Small molecule	10 mg	—

Indications